ING1b is a candidate tumor suppressor gene and a nuclear protein. ING1b promoter methylation status of these methylation positive cases. Statistical significant correlation between methylation and mRNA expression (P ¼ 0.006) was demonstrated. Treatment with demethylating drug, 5 0 -aza-2 0 -deoxycytidine, resulted in dosagedependent elevated mRNA expression of p33
Introduction

p33
ING1b , the inhibitor of growth 1b gene, has been identified as a novel growth inhibitor and tumor suppressor gene. It is located on chromosome 13q34, and encodes a 279-amino acid 32-kDa-nuclear protein (1) . The p33
ING1b is the most widely expressed isoform amongst the other isoforms in the ING1 family (2--4) and is the focus of the current study. Suppression of p33
ING1b is associated with the loss of cellular growth control and immortalization, while its overexpression arrests cells in the G 0 /G 1 phase of the cell cycle (5) . Allelic loss of p33 ING1b was reported in head and neck, and brain cancers (6--9) ; and reduced expression of it has been found in lymphoid malignancy, esophageal, gastric, brain and breast cancers (9--14) , suggesting that the reduced expression of p33
ING1b might contribute to tumorigenesis. However, mutation in the p33 ING1b gene is rare (9, 12, 15, 16) , and hence, other mechanisms may have contributed to the reduced expression of this gene.
DNA methylation is an enzyme-induced chemical modification, which usually occurs in cytosine--guanine dinucleotiderich regions, CpG islands and within the gene promoter regions (17) . Altered methylation patterns have been observed in many cancers (18--22) . Decreased methylation may allow the expression of previously quiescent proto-oncogenes or imprinted genes to become active and induce cell proliferation. In contrast, increased methylation at the promoter regions of a tumor suppressor gene may result in silencing them through the inhibition of transcription and thereby reducing the suppression of cell proliferation (17) . The p33
ING1b gene promoter region (8) is rich in CpG dinucleotides. CpG islands have been identified by computational analysis by CpGPlot (http://www.bei.ac.uk/emboss/cpgplot/ ) and also illustrated in Ensembl Human Genome database (Ensembl gene: ENSG00000153487). It has been suggested that p33 ING1b might serve as a 'class 2 tumor suppressor' by inactivating RNA expression rather than by mutation or genetic loss (11) . The possible involvement of the epigenetic factor of CpG methylation affecting the transcript level of p33
ING1b tumor suppressor gene has not been reported.
In the present study, we used methylation specific polymerase chain reaction (MSP), bisulfite sequencing (BSG) method as well as methylation-sensitive enzyme restriction PCR to analyze the p33 ING1b methylation pattern in the ovarian cancers. As far as we know, we are the first group to study promoter CpG methylation status of p33
ING1b in human cancers. Immunohistochemical study using monoclonal antibody (CAb1-4) recognizing p33
ING1b performed on tissue microarray (TMA) were used to assess the protein expression pattern of these tumors. The mRNA expression was assessed by realtime quantitative reverse transcription polymerase chain reaction (RT--PCR) assay. Mutation analysis and allelic loss study were also performed.
Materials and methods
Clinical samples and cell lines
The paraffin embedded tissues of ovarian cancer (111 cases-62 from Beijing and 49 from Hong Kong) were retrieved from the Departments of Pathology, People's Hospital, Peking University, Beijing, and Queen Mary Hospital, the University of Hong Kong, Hong Kong. Thirty-two of forty-nine ovarian cancers with available frozen samples of cancer and corresponding non-tumor blocks were also retrieved from the archival tissue bank of the latter department. Fallopian tube was chosen as the non-tumor counterpart to ovarian epithelium as both are of M€ u ullerian duct origin (23) . Normal ovarian tissue was collected from six patients, from individuals who had undergone total abdominal hysterectomy and bilateral salphingo-oophorectomy due to noncancerous diseases. All the cases were verified by two surgical pathologists. The criteria used for histological type of tumor were based on the classification of the World Health Organization (Tables I and II) . The clinical data of the patients from Hong Kong were retrieved and reviewed by the gynecological oncologist in the Department of Obstetrics and Gynecology, Queen Mary Hospital, the University of Hong Kong.
The human ovarian cancer cell lines, OVCA3 and SKOV3 were maintained in DMEM with 4 mM L-glutamine and McCoy's 5a with 1.5 mM L-glutamine (Life Technologies, Inc., Gaithersburg, MD, USA) respectively, supplemented with 10% fetal bovine serum in a humidified incubator at 37 C and an atmosphere of 5% carbon dioxide.
Tissue microarray
Before TMA construction, H&E-stained sections of each sample case were reviewed to define tumor representative regions. All tumor areas in the H&E sections were circled. Four to six cylindrical tissue cores with a diameter 0.6 mm were then punched randomly from previously defined tumor region of each tissue block and brought into a recipient paraffin block using DNA-TMA instrument (24, 25) . Forty to fifty six tissue samples were embedded in a single composite paraffin block.
Immunohistochemistry TMA sections, 5 mm thick, were cut and mounted on 2% aminopropyltriethoxysilane-coated glass slides. One section from each TMA block was H&E-stained and another section was examined for p33 ING1b expression. The monoclonal antibody (CAb1-4) recognizing p33
ING1b (26, 27 ) was supplied by Prof. Raibowol (Department of Biochemistry, University of Calgary, Canada). The sections were deparaffinized, and endogenous peroxidase activity was blocked using 1% hydrogen peroxide in methanol. The sections were then placed in a microwave oven for 15 min at 95 C in 10 mM Tris--HCl buffer (pH 7.4) for antigen retrieval. Non-specific antigen was blocked using 10% normal rabbit serum in 2% bovine serum albumin for 30 min. Sections were incubated using the CAb1-4 antibody overnight at 4 C. Biotin-labeled antimouse immunoglobulin was used as secondary antibody. The sections were then incubated with an avidin--biotin--peroxidase complex. 3,3-Diminobenzidine-hydrogen peroxide was used as chromogen. The sections were dehydrated in ethanol, cleared in xylene and mounted. A paraffin embedded tissue of normal stomach was used as a positive control (11) , whereas a section incubated in rabbit serum instead of primary antibody was used for comparison as a negative control.
For assessment of immunoreactivity, both the intensity and percentage of positive staining were evaluated. Staining intensity was graded as À (negative), þ (weak positive) and þþ (strong positive). A case was considered to be negative if there was no staining or weak staining involving 510% cells were found.
DNA and RNA extraction Twenty to thirty sections, 15 mm thick, were cut for each paraffin embedded tissue of cancer and deparaffinized for genomic DNA extraction using conventional phenol/chloroform preceding proteinase K digestion method. DNA extracted from the frozen tissues of 32 cancer cases was processed in a similar manner. Total RNA was also extracted from the frozen tumor and non-tumor counterpart tissues of the 32 cancer cases using TRIZOL (Invitrogen, Carlsbad, CA) according to the manufacturer's instruction. The dissected tissues were homogenized in 1 ml of TRIZOL and mixed with chloroform followed by isopropanol precipitation. The extracted RNA was suspended in RNase-free water. The quality and quantity of DNA and RNA were checked by agarose gel electrophoresis and spectrophotometry. All of the cancer tissue used were dissected and H&E stained, and they were confirmed by the clinical pathologist to have 475% tumor cells.
RNA expression study
One microgram of total RNA was synthesized to cDNA by reverse transcription. The synthesized cDNA was used for real--time quantitative RT--PCR by TaqMan assay. The TaqMan probe was 5 0 FAM-AGT GCT ACG AGC GCT TCA GTC GCG-TAMRA 3 0 , and the primers were ING1bF 5 0 -GAG ATC GAC GCG AAA TAC CAA-3 0 and ING1bR 5 0 -CTC CTG GCT GCG GA TCA G-3 0 , where the probe and primers were specific to the p33 ING1b transcript. The quantitative expression levels of p33 ING1b and the housekeeping gene, TBP, were measured against the calibrated curve constructed by the linearized plasmid containing the gene insert as described previously (23). The expression level of p33 ING1b was normalized with that of TBP whose probe and primer sequences were described previously (23) . The normalized value of p33
ING1b in the tumor was compared with that in the non-tumor counterpart of each case for a total of 32 ovarian cancer cases. The real-time quantitation was performed on ABI 7700 Real-time PCR machine (Applied Biosystems, Foster City, CA), and every sample was triplicated for each run of measurement.
Allelic loss and mutation analyses
The 32 ovarian cases studied had genomic DNA available from tumor and nontumor counterpart tissues. These paired cases (same cases used in RNA expression study) were used for p33
ING1b allelic loss analysis. Three fluorescent labeled micorsatellite markers (5 0 flanking D13S278 and D13S796, and 3 0 flanking D13S285 and p33
ING1b
) were used. A PCR was performed in a 10 ml volume containing 1 Â PCR Gold Buffer, 2 mM MgCl 2 , 250 mM dNTP, 400 mM primers, and 1 U AmpliTaq Gold DNA polymerase (Applied Biosystems). The PCR consisted of an initial denaturation step at 95 C for 10 min, 40 cycles of 15 s at 95 C, 1 min at 60 C and 30 s at 72 C, and an additional 10 min extension step at 72 C. The amplified microsatellite fragments were run on ABI PRISM 377 sequencer (Applied Biosystems), using GeneScan and Genotype software (Applied Biosystems) to analyze the allelic loss status of each case. In informative cases, allelic loss on the marker was defined as a decrease of 50% of the signal intensity of one of the alleles compared with that of another allele.
Primers were designed specific to flank and amplify the two fragments which encoded the exons 1 and 2 of p33 C. The PCR product was purified and then used for direct sequencing on ABI PRISM 377 sequencer (Applied Biosystems).
Methylation specific polymerase chain reaction and bisulfite sequencing Two micrograms of DNA was modified by treatment with sodium bisulfite as described previously (23) . Methylation and unmethylation-sensitive primers were specifically designed to detect methylation status of CpG dinucleotides (Figure 1 ). The sequences of primers used to amplify and detect unmethylated p33 Genomic DNA not treated for bisulfite modification was used as reaction negative control. MSP products were separated on 2% agarose gel containing ethidium bromide. Representative cases of MSP products were subject to direct sequencing. All the methylationpositive cases detected by MSP were analyzed by BSG.
BSG was carried out using methylation unbiased primers on sodium bisulfite modified tumor DNA to amplify the region harboring the MSP product fragment as shown in Figure 1 . The primer sequences were as follows: (forward) 5 0 -GGG AGA YGA TAT AAA GGG AGG G-3 0 and (reverse) 5 0 -TAA ATA ATA CCC CCC RAA CTC TTA CTA CTA-3 0 . The reaction was performed at: 95 C for 4 min, followed by 40 cycles of 94 C for 10 s, 55 C for 30 s, and 72 C for 45 s, finally 72 C for 3 min. The amplified product was cloned into pGEM-T Easy vector and ten clones were randomly selected for sequencing.
Demethylation experiment and methylation-sensitive enzyme restriction PCR The cell lines of OVCA3 and SKOV3 previously found to have methylation of p33
ING1b by MSP and BSG were treated with a demethylating drug, 5 0 -aza-2 0 -deoxycytidine (5 0 -AC) (Sigma, St Louis, MO) (28) . The cell lines that reached 80% confluence were treated with 5 0 -AC at concentration gradients of 0, 0.1, 1.0, 10, 50, 100 mM for 5 days and the experiment was repeated. The TRIZOL reagent was added directly to the cells for RNA extraction. The RNA expression of p33
ING1b was quantitated using TaqMan real-time RT-PCR as described earlier. The genomic DNA from the cell lines was then isolated from the organic phase residue of the TRIZOL after RNA extraction. BSG was carried on these DNAs.
Methylation-sensitive enzymes (HpaII and HhaI) and methylationinsensitive enzyme (MspI) digested the DNA extracted from the ovarian cell lines OVCA3 and SKOV3. The digested DNAs were purified by ethanol precipitation. The purified DNA served as the template in PCR where the primers were designed to flank the enzyme restriction sites: RE-1F fragment (forward) 
Statistical analysis
Software of SPSS 10.1 for Windows (SPSS Inc., Chicago, IL) was used to perform the statistical analysis. Comparisons were made by Chi-square test, Fisher's Exact test and Wilcoxon test (two-sided) where applicable. P-value of 50.05 was taken to be statistically significant. Correlation between experimental data and clinical data was also performed. Kaplan--Meier analysis and log-rank test were used for disease free interval and survival analysis.
Results
Immunohistochemical analysis Positive p33
ING1b staining was observed as a nuclear pattern. p33
ING1b nuclear staining was seen in the normal gastric fundic glands epithelial cells, i.e. the positive control ( Figure 2 ). Weak or negative p33
ING1b staining was observed in 25.2% (28/111) of carcinoma cases (Tables I and II (Tables I and IV) .
mRNA expression
The mRNA expression of p33
ING1b studied in 32 ovarian cancers showed significant overall reduced expression in tumor compared to that in non-tumor (P-value ¼ 0.0137, Wilcoxon test) ( Figure 3A) . In 17 of 32 (53.1%) ovarian cancer cases a significant 2-to 5-fold reduction and absence of p33
ING1b expression was demonstrated. By this 2-fold reduction criteria in tumor, the reduction of mRNA expression was found to correlate significantly with decreased p33 (Table IV) .
Allelic loss and mutation analyses Allelic loss at the p33
ING1b loci, 13q33-34, was observed in 8 out of 32 (25%) ovarian cancer cases in which at least one marker demonstrated allelic loss (Table III) . Among these eight cases, six cases were found to have allelic loss in at least two informative loci in tumor. Overall, our allelic loss results showed statistical significant correlation with reduction of p33
ING1b protein and mRNA expression but not promoter methylation (P-values ¼ 0.031, 0.030 and 0.95, Fisher's exact test, respectively) in the studied ovarian tumors (Table III) . In these 32 cases, no mutation was detected in either fragments corresponding to the coding sequence of p33 ING1b (data not shown). No significant correlation was noted between allelic
Transcriptional start site Fig. 1 . The region between À95 and À410 of the p33ING1b promoter was identified in silico to be a CpG island (shaded area). The solid arrows indicate the locations of the methylation and unmethylation specific primers used in the MSP assay, and the dotted arrows indicate the locations of the methylation unbiased primers for bisulfite sequencing. Circles denote the positions of CpG dinucleotides. Illustration was generated from CpG island prediction by MethPrimer (http://itsa.ucsf.edu/~urolab/methprimer). loss and the clinical data of the tumor histological types and stage (P-values ¼ 0.10 and 0.43, Fisher's exact test, respectively) (Table IV) .
Epigenetic and genetic alterations
Methylation analysis MSP analysis was successfully performed on 88 of 111 cases of paraffin embedded carcinoma tissues. Results showed p33
ING1b promoter methylation in 21 out of 88 (23.9%) cases of tumors (Table II) . Promoter methylation detected in paraffin embedded and frozen tissues were of similar proportion: 14/56 (25%) and 7/32 (22%), respectively. Promoter methylation could not be detected from non-tumor counterparts of cancer cases or from all six normal ovarian tissues by MSP and BSG. The BSG results of the tumor cases and the two cell lines found to be methylation positive by MSP were summarized in Table V . The regions of À213 to À235 and À339 to À361 were the primers region used in MSP assay. The CpGs in these regions were frequently methylated (Table V and Figure 4A and B), and their frequencies ranged from 0--75%, and predominantly 50--75% (Table V) .
Overall statistical significant correlation between p33
ING1b promoter methylation and mRNA expression was noted in the 32 studied frozen tissue samples (P-value ¼ 0.006, Fisher's exact test). Seven cases with promoter methylation demonstrated a reduction in p33 ING1b mRNA expression in the tumor. It was also observed that nearly all the cases with reduced p33
ING1b mRNA or protein expression were associated with either allelic loss or promoter hypermethylation in tumor (Table III) . Nevertheless, correlation between the p33 ING1b protein expression and promoter methylation in the overall ovarian cancer cases failed to reach statistical significance (P-value ¼ 0.77, Fisher's exact test) (Table II) . There was no significant correlation between the promoter methylation and the clinical data of the tumor histological type and clinical stage (P-values ¼ 0.77 and 0.31, Fisher's exact test, respectively) (Table IV) .
We were able to demonstrate p33 ING1b promoter methylation in the ovarian cancer cell lines OVCA3 and SKOV3. Heterogeneous promoter methylation pattern was detected in both cell lines, with both methylated and unmethylated alleles detected by MSP and BSG ( Figure 4B and Table V) . Methylated and unmethylated products from some representative cases were directly sequenced and confirmed ( Figure 4C ). Methylation-sensitive enzyme restriction PCR results showed that successful amplification was detected in the DNA digested by the enzymes HpaII and HhaI, but not in that digested by the enzyme MspI ( Figure 4C ). This implied the presence of the methylated and unmethylated CpGs in these methylationsensitive enzyme restriction sites which concurred with the BSG results. Treatment by the demethylating drug 5 0 -AC on Epigenetic and genetic alterations the cell lines was successfully performed. After 5 0 -AC treatment, the cell proliferative ability was apparently decreased. Using quantitative real-time PCR, the mRNA expression of p33 ING1b was found to increase after the 5 0 -AC treatment. OVCA3 and SKOV3 were found to have highest elevated expression of p33
ING1b after treatment by 5 0 -AC at the optimal concentrations of 50 and 0.1 mM, respectively ( Figure 5 ). This suggested a dosage-dependent differential effectiveness of the demethylating drug on these cancer cell lines. BSG was performed on both cell lines after treatment with the optimal Table V . Summary of BSG results of all of the ovarian tumor (OC) cases found to be methylation positive by MSP and of the five representative OC cases found to be methylation negative (i.e. unmethylation positive) by MSP assay The CpG dinucleotides upstream to the transcriptional start site of p33
ING1b (in bold) were the priming regions of the primers used in MSP. *: absence of methylated CpG in selected clones, : methylation found in 10--25% selected clones, : methylation found in 26--50% selected clones, : methylation found in 51--75% selected clones, *: methylation found in 475% selected clones. OVCA3/5AC and SKOV3/5AC: the two ovarian cancer cell lines treated by 5 0 -AC. Normal ovaries: all six normal ovarian epithelial tissues. M and U þve ctrl: methylation-positive control (sodium bisulfite treated universal methylated DNA) and unmethylation-positive control (sodium bisulfite treated normal placenta DNA).
5
0 -AC concentration. Most of the CpGs were unmethylated (Table V) and the 5 0 -AC could almost completely eliminate CpG DNA methylation.
In the samples we studied, the patients sensitive to the chemotherapy treatment would have better survival outcome (P-value 5 0.0001, log-rank test, data not shown). Clinical parameters of the studied cases were analyzed with the expression level, allelic loss and promoter methylation status of p33
ING1b results. No significant correlation with tumor histological type and stage was shown. There was also no statistically significant correlation between the experimental results (the protein, mRNA expression level, allelic loss and promoter methylation status of p33
ING1b
) and other clinical parameters: the chemosensitivity (P-values ¼ 0.82, 0.82, 0.95, 0.80, Fisher's exact test, respectively) (Table IV) , patients' disease free interval (P-values ¼ 0.35, 0.31, 0.24, and 0.31, log-rank test, respectively) (data not shown), and survival data (P-values ¼ 0.51, 0.85, 0.88, and 0.85, log-rank test, respectively) (data not shown).
Discussion
The p33
ING1b gene has been proposed to be a candidate tumor suppressor. Its tumor suppressive functions, including G 0 /G 1 cell cycle arrest, anchorage-dependent growth, senescence and
